Search Results

You are looking at 51 - 60 of 979 items for :

  • "NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines" x
  • Refine by Access: All x
Clear All
Full access

David G. Pfister, Sharon Spencer, David M. Brizel, Barbara Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Cristina P. Rodriguez, Sandeep Samant, David E. Schuller, Jatin P. Shah, Randal S. Weber, Gregory T. Wolf, Frank Worden, Sue S. Yom, Nicole R. McMillian, and Miranda Hughes

selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck (H&N) Cancers focuses on glottic laryngeal cancer, which is the most common type of laryngeal cancer and has an excellent cure rate. The complete version of

Full access

Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt, Dale Bixby, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Thomas W. LeBlanc, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Margaret R. O’Donnell, Rebecca Olin, Deniz Peker, Alexander Perl, Daniel A. Pollyea, Keith Pratz, Thomas Prebet, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Matthew Wieduwilt, Kristina M. Gregory, OCN, Lydia Hammond, and Ndiya Ogba

. Clinical trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. PLEASE NOTE The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a

Full access

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Naresh Bellam, William Blum, Michael W. Boyer, Hetty E. Carraway, Peter F. Coccia, Steven E. Coutre, Jennifer Cultrera, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Haydar Frangoul, Olga Frankfurt, Salil Goorha, Michael M. Millenson, Susan O'Brien, Stephen H. Petersdorf, Arati V. Rao, Stephanie Terezakis, Geoffrey Uy, Meir Wetzler, Andrew D. Zelenetz, Maoko Naganuma, and Kristina M. Gregory

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Acute Lymphoblastic Leukemia (ALL) were developed as a result of meetings convened by a multidisciplinary panel of ALL experts, with the goal of providing recommendations on standard

Full access

William T. McGivney

The National Comprehensive Cancer Network (NCCN) and our 21 member institutions are dedicated to improving the care available to patients around the world. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) and the attendant

Full access

Robert W. Carlson and Eric Jonasch

NCCN Evidence Blocks to Guide Decision-Making NCCN recently introduced NCCN Evidence Blocks into a number of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to assist clinicians and patients as they grapple with treatment

Full access

Waleed A. Hassen, Farrok A. Karsan, Farhat Abbas, Yasar Beduk, Ahmed El-Khodary, Marwan Ghosn, Jamal Khader, Raja Khauli, Danny M. Rabah, Ali Shamseddine, and Sandy Srinivas

Africa (MENA) region is not completely known. A prostate cancer committee was established to modify the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Prostate Cancer for adaptation and implementation in the MENA region. The objective

Full access

Andrew D. Zelenetz and Pamela S. Becker

granulocyte colony-stimulating factor (G-CSF) filgrastim-sndz. Filgrastim-sndz is now listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors (MGFs) and is part of many drug formularies. The oncology community

Full access

Jerald P. Radich

-positive (Ph+) marrow metaphases,” as they correspond to long-term outcomes such as progression-free and overall survival (OS). The treatment options recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for chronic-phase CML

Full access

Arti Hurria

. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Senior Adult Oncology include a comprehensive geriatric assessment that can be used to help predict the risk of toxicity from cancer treatment in older patients. Along with age

Full access

Kenneth C. Anderson

Practice Guidelines in Oncology (NCCN Guidelines) for multiple myeloma regarding transplant candidates were updated to include this triplet as an initial treatment option under “other regimens.” This joins a growing list of triplets that greatly increase